News and Trends 20 Mar 2019
Czech Cell Therapy Increases Survival in Ovarian Cancer by 62%
The Czech biotech company Sotio has shown in a phase II trial that its cellular immunotherapy can decrease the risk of a patient dying from ovarian cancer by 62%. The cell therapy was tested in people with the most severe stages of recurrent ovarian cancer, in combination with second-line chemotherapy when cancer returned after […]